Gastroenterology
From the Journals
Registry data support lowering CRC screening age to 45
Existing research gaps on the rates of younger-onset colorectal neoplasia need to be addressed to support these recommendations.
From the Journals
Bowel ultrasound may overtake colonoscopy in Crohn’s
Bowel ultrasound may be the simple alternative to more costly and poorly tolerated colonoscopies.
From the Journals
Higher adalimumab dosing regimens may have benefit in ulcerative colitis
The findings also show that weekly adalimumab maintenance dosing “may be appropriate for some patients.”
From the Journals
Can green tea extract protect against colorectal adenomas?
Green tea extract taken over 3 years was well tolerated but had no significant effects, according to the results of a large randomized controlled...
From the Journals
Can colorectal ESD succeed in outpatient settings?
Endoscopic submucosal dissection may yet escape the inpatient setting in Asian countries and find widespread adoption in the West, too.
Sponsored Supplement
Three Clinical Studies Demonstrating Safety and Efficacy of Treatment for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) in Adults
From the Journals
RFA has long-lasting protective effects in esophageal cancer
A 10-year report from the United Kingdom shows the benefits are durable for patients with Barrett’s esophagus.
From the Journals
Topical steroid shows promise for EOE
Formulation designed for the esophagus could replace repurposed inhalants in eosinophilic esophagitis.
From the Journals
AGA Clinical Practice Update: Commentary on noninvasive CRC screening
How to tailor screening based on CRC risk, and how to be sure screening is effective.
From the Journals
Three popular IBS diets found equivalent
The three diets have different origins and methodologies, but all are designed to reduce the abdominal pain, bloating, and altered bowel habits....
From the Journals
AGA Clinical Practice Guidelines: Systemic HCC therapy
New therapies offer plenty of options, but evidence is sparse.
Latest News
C. difficile vaccine: Pfizer’s phase 3 CLOVER trial shows mixed results
“I am impressed, from the limited data that have been made available, that the vaccine appears to have efficacy of around 50% for reducing CDI.”...